ArticleJournal of the American Society of Nephrology : JASN2011
Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.
Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders.Nutrients · 2022Review
- D-ribose is elevated in T1DM patients and can be involved in the onset of encephalopathy.Aging · 2019Article
- Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.World journal of nephrology · 2017Review
- Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.International journal of molecular sciences · 2017Review
- [High glucose dialysate enhances peritoneal fibrosis through upregulating glucose transporters GLUT1 and SGLT1].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Article
- The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.Stem cells translational medicine · 2016Article
- A review of rodent models of peritoneal dialysis and its complications.International urology and nephrology · 2015Review
- Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid.Frontiers in medicine · 2015Article
- Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?Current opinion in nephrology and hypertension · 2014Review
- The beneficial role of thiamine in Parkinson disease.CNS neuroscience & therapeutics · 2013Review
- Article
- Cellular effects of everolimus and sirolimus on podocytes.PloS one · 2013Article
- Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.Nature reviews. Nephrology · 2012Review
- Level of 8-OHdG in drained dialysate appears to be a marker of peritoneal damage in peritoneal dialysis.International journal of nephrology and renovascular disease · 2012Article
- Pharmacologic targets and peritoneal membrane remodeling.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisReview
- Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Seminars in dialysisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual renal function and the integrity of the peritoneal membrane contribute to morbidity and mortality among patients treated with peritoneal dialysis. Glucose and its degradation products likely contribute to the deterioration of the remnant kidney and damage to the peritoneum. Benfotiamine decreases glucose-induced tissue damage, suggesting the potential for benefit in peritoneal dialysis. Here, in a model of peritoneal dialysis in uremic rats, treatment with benfotiamine decreased peritoneal fibrosis, markers of inflammation, and neovascularization, resulting in improved characteristics of peritoneal transport. Furthermore, rats treated with benfotiamine exhibited lower expression of advanced glycation endproducts and their receptor in the peritoneum and the kidney, reduced glomerular and tubulointerstitial damage, and less albuminuria. Increased activity of transketolase in tissue and blood contributed to the protective effects of benfotiamine. In primary human peritoneal mesothelial cells, the addition of benfotiamine led to enhanced transketolase activity and decreased expression of advanced glycation endproducts and their receptor. Taken together, these data suggest that benfotiamine protects the peritoneal membrane and remnant kidney in a rat model of peritoneal dialysis and uremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.